Form 8-K - Current report:
SEC Accession No. 0001178913-24-003866
Filing Date
2024-11-29
Accepted
2024-11-29 06:00:53
Documents
17
Period of Report
2024-11-29
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2432408.htm   iXBRL 8-K 57036
2 EXHIBIT 3.1 exhibit_3-1.htm EX-3.1 7635
3 EXHIBIT 4.1 exhibit_4-1.htm EX-4.1 12523
8 image00001.jpg GRAPHIC 2743
  Complete submission text file 0001178913-24-003866.txt   275629

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA slxn-20241129.xsd EX-101.SCH 4742
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20241129_def.xml EX-101.DEF 18739
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20241129_lab.xml EX-101.LAB 28484
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20241129_pre.xml EX-101.PRE 21038
20 EXTRACTED XBRL INSTANCE DOCUMENT zk2432408_htm.xml XML 6718
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 241513009
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)